Investing.com - Moderna (NASDAQ: MRNA) reported third quarter EPS of $-9.53, $7.63 worse than the analyst estimate of $-1.90. Revenue for the quarter came in at $1.8B versus the consensus estimate of $1.4B.
Guidance
Moderna sees FY 2023 revenue of $6.00B versus the analyst consensus of $6.45B.
Moderna's stock price closed at $76.20. It is down -29.57% in the last 3 months and down -48.34% in the last 12 months.
Moderna saw 0 positive EPS revisions and 11 negative EPS revisions in the last 90 days. See Moderna's stock price’s past reactions to earnings here.
According to InvestingPro, Moderna's Financial Health score is "great performance".
Check out Moderna's recent earnings performance, and Moderna's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar